Symptom control in children and adolescents with attention-deficit/ hyperactivity disorder on switching from immediate-release MPH to OROS® MPH: Results of a 3-week open-label study

European Child and Adolescent Psychiatry

Volumn 14, Issue 6, 2005, Pages 297-304

  Remschmidt, H ^a   Hoare, P ^b   Ettrich, C ^c   Rothenberger, A ^d   Santosh, P ^e   Schmidt, M ^f   Spender, Q ^g   Tamhne, R ^h   Thompson, M ⁱ   Tinline, C ^j   Trott, G E ^k   Medori, R ^l  

^a Klinik für Kinder und Jugendpsychiatrie   (Germany)

^b ROYAL HOSPITAL FOR SICK CHILDREN   (United Kingdom)

^c UNIVERSITY OF LEIPZIG   (Germany)

^d UNIVERSITY OF GÖTTINGEN   (Germany)

^e KING'S COLLEGE LONDON   (United Kingdom)

^f CENTRAL INSTITUTE OF MENTAL HEALTH   (Germany)

^g SUSSEX PARTNERSHIP NHS FOUNDATION TRUST   (United Kingdom)

^h Leicestershire County and Rutland PCT   (United Kingdom)

ⁱ Ashurst Hospital   (United Kingdom)

^j Therapy Service   (United Kingdom)

^k Privatpraxis   (Germany)

^l JANSSEN CILAG GMBH   (Germany)

more..

Author keywords

ADHD; CONCERTA ; Long acting; Methylphenidate; OROS

Indexed keywords

METHYLPHENIDATE; OROS;

ABDOMINAL PAIN; ADOLESCENT; AGGRESSION; ARTICLE; ATTENTION DEFICIT DISORDER; CHILD; CLINICAL FEATURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG FORMULATION; FEMALE; HEADACHE; HUMAN; MAJOR CLINICAL STUDY; MALE; PARENT; SIDE EFFECT; SLEEP DISORDER; TEACHER; TIC; TREATMENT OUTCOME; WEIGHT REDUCTION; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG SAFETY; RATING SCALE; TREATMENT RESPONSE; UNITED STATES; UNSPECIFIED SIDE EFFECT;

ADOLESCENT; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DELAYED-ACTION PREPARATIONS; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; HUMANS; MALE; METHYLPHENIDATE; PERSONALITY ASSESSMENT; TREATMENT OUTCOME;

EID: 26444518110     PISSN: 10188827     EISSN: 1435165X     Source Type: Journal    
DOI: 10.1007/s00787-005-0467-6     Document Type: Article

References (18)

1. AACAP (2002) Practice parameter for the use of stimulant medications in the treatment of children, adolescents, and adults. J Am Acad Child Adolesc Psychiatry 41(2 Suppl):26S-49S
2. Atkins MS, Pelham WE, Licht MH (1989) The differential validity of teacher ratings of inattention/overactivity and aggression. J Abnorm Child Psychol 17(4):423-435
3. Greenhill LL, Swanson JM, Vitiello B, Davies M, Clevenger W, Wu M, Arnold LE, Abikoff HB, Bukstein OG, Conners CK, Elliott GR, Hechtman L, Hinshaw SP, Hoza B, Jensen PS, Kraemer HC, March JS, Newcorn JH, Severe JB, Wells K, Wigal T (2001) Impairment and deportment responses to different methylphenidate doses in children with ADHD: the MTA titration trial. J Am Acad Child Adolesc Psychiatry 40(2):180-187
4. Klassen A, Miller A, Raina P, Lee SK, Olsen L (1999) Attention-deficit hyperactivity disorder in children and youth: a quantitative systematic review of the efficacy of different management strategies. Can J Psychiatry 44(10):1007-1016
5. Kutcher S, Aman M, Brooks SJ, Buitelaar J, van Daalen E, Fegert J, Findling RL, Fisman S, Greenhill LL, Huss M, Kusumakar V, Pine D, Taylor E, Tyano S (2004) International consensus statement on attention-deficit/ hyperactivity disorder (ADHD) and disruptive behaviour disorders (DBDs): clinical implications and treatment practice suggestions. Eur Neuropsychopharmacol 14(1):11-28
6. Loney J, Milich R (1982) Hyperactivity, inattention, and aggression in clinical practice. In: Wolraich M, Routh DK (eds) Advances in Development and Behavioral Pediatrics. JAI Press. Greenwich, CT, pp 113-147
7. Miller A, Lee SK, Raina P (1999) Assessment of Attention Deficit/Hyperactivity Disorder: A Canadian Perspective - Technology Overview. In: Shukla KV, Otten N (eds) Canadian Coordinating Office for Health Technology Assessment
8. Pelham WE, Gnagy EM, Burrows-Maclean L, Williams A, Fabiano GA, Morrisey SM, Chronis AM, Forehand GL, Nguyen CA, Hoffman MT, Lock TM, Fielbelkorn K, Coles EK, Panahon CJ, Steiner RL, Meichenbaum DL, Onyango AN, Morse GD (2001) Once-a-day Concerta methylphenidate versus three-times-daily methylphenidate in laboratory and natural settings. Pediatrics 107(6):E105
9. Pelham WE, Gnagy EM, Chronis AM, Burrows-MacLean L, Fabiano GA, Onyango AN, Meichenbaum DL, Williams A, Aronoff HR, Steiner RL (1999) A comparison of morning-only and morning/late afternoon Adderall to morning-only, twice-daily, and three times-daily methylphenidate in children with attention-deficit/ hyperactivity disorder. Pediatrics 104(6):1300-1311
10. Pelham WE, Milich R, Murphy DA, Murphy HA (1989) Normative data on the IOWA Conners Teacher Rating Scale. J Clin Child Psychol 18:259-262
11. Schachter HM, Pham B, King J, Langford S, Moher D (2001) How efficacious and safe is short-acting methylphenidate for the treatment of attention-deficit disorder in children and adolescents? A meta-analysis. CMAJ 165(11):1475-1488
12. Stein MA, Greenhill LL (2002) Once-daily Concerta (MPH) for adolescents and adult with ADHD. Int J Neuropsychopharmacol 5(Suppl 1):S162
13. Swanson J (2003) Compliance with stimulants for attention-deficit/ hyperactivity disorder: issues and approaches for improvement. CNS Drugs 17(2):117-131
14. Swanson J, Greenhill L, Pelham W, Wilens T, Wolraich M, Abikoff H, Atkins M, August G, Biederman J, Bukstein O, Conners CK, Efron L, Fiebelkorn K, Fried J, Hoffman M, Lambrecht L, Lerner M, Leventhal B, McBurnett K, Morse E, Palumbo D, Pfiffner L, Stein MA, Wigal S, Winans E (2000) Initiating CONCERTA (OROS methylphenidate HCI) qd in children with attention-deficit hyperactivity disorder. J Clin Res 3:59-76
15. Swanson JM, Lerner MA, Gupta S, Shoulson I, Wigal S (2003) Development of a new once-a-day formulation of methylphenidate for the treatment of ADHD. Arch Gen Psychiatry 60(2):204-211
16. Wilens T, Pelham W, Stein MA, Conners CK, Abikoff H, Atkins M, August G, Greenhill L, McBurnett K, Palumbo D, Swanson J, Wolraich M (2003) ADHD treatment with once-daily OROS® methylphenidate: interim 12-month results from long-term open-label study. J Am Acad Child Adolesc Psychiatry 42(4):424-433
17. th Annual Meeting of the American Psychiatric Association, Philadelphia, PA, May 18-22:2002
18. Wolraich ML, Greenhill LL, Pelham W, Swanson J, Wilens T, Palumbo D, Atkins M, McBurnett K, Bukstein O, August G (2001) Randomized, controlled trial of OROS methylphenidate once a day in children with attention-deficit/ hyperactivity disorder. Pediatrics 108(4):883-892